Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Michael Young who wrote (3799)	5/15/2001 8:46:20 PM
From: Biomaven	Read Replies (1) \| Respond to of 52153

rate cuts mean that institutional money will be attracted to more cyclical market sectors I'm familiar with that reasoning, however I've normally seen it applied to the drug stocks not the biotechs. Not many people consider biotechs "defensive" although of course they perhaps have the lowest fundamental cyclicality of any sector. My view is that biotechs are primarily liquidity-driven. Certainly their price moves are more closely tied to NASD rather than to the more closely related (on fundamentals) DRG index. This is a view of what sectors are claimed to perform best at different stages of the economic cycle: stockcharts.com This is the current relative performance (unfortunately drugs and biotechs are not included): stockcharts.com Peter